Epigenomics Profile

Performance

   

Odds of Distress

Check how we calculate scores
Equity ratings for Epigenomics Ag Berli are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting August 15, 2019 and ending today November 13, 2019. Click here to learn more.

Epigenomics Profile

Epigenomics AG, a molecular diagnostics company, focuses on developing and commercializing in vitro diagnostic tests for the screening, early detection, and diagnosis of cancer in Germany and internationally. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics is traded on BATS Exchange in USA. more
NameEpigenomics Ag Berli
CEOGregory HamiltonView All
Macroaxis Advice
InstrumentUSA OTC Stock View All
Business AddressGeneststrasse 5
ExchangeBATS Exchange
BenchmarkDOW
Websitewww.epigenomics.com
Phone49 30 243 450
CurrencyUSD - US Dollar
Epigenomics Ag Berli [EPGNF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with current market capitalization of 39.57 M. Epigenomics Ag Berli has 24.01 M outstanding shares. EPIGENOMICS AG BE has accumulated about 15 M in cash with (8.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.73.
Check Epigenomics Probability Of Bankruptcy

Epigenomics Target Price Odds Analysis

Odds Below 1.06HorizonTargetOdds Above 1.06
1.68%30 days 1.06 98.31%
Based on normal probability distribution, the odds of Epigenomics to move above current price in 30 days from now is about 98.0 (This Epigenomics Ag Berli probability density function shows the probability of Epigenomics OTC Stock to fall within a particular range of prices over 30 days) .

Epigenomics Ag Berli Risk Profiles

Epigenomics Key Fundamentals

Epigenomics Against Markets

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

Epigenomics Corporate Management

Antje Zeise Manager Investor Relations
Guenther Reiter Member of the Supervisory Board
Ann Kessler Member of the Supervisory Board
Helge Lubenow Member of the Supervisory Board
Additionally see Investing Opportunities. Please also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Search macroaxis.com